Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin

Autor: Pehrsson, S., Johansson, K. J, Janefeldt, A., Sandinge, A.‐S., Maqbool, S., Goodman, J., Sanchez, J., Almquist, J., Gennemark, P., Nylander, S. ^*

Publikováno v: In Journal of Thrombosis and Haemostasis June 2017 15(6):1213-1222

Figure S1 from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Autor: Darren A.E. Cross, Zack Cheng, Lars Farde, Paul D. Smith, James W.T. Yates, Richard A. Ward, M. Raymond V. Finlay, Natasha A. Karp, Albert D. Windhorst, Mohammad Mahdi Moein, Ana Vazquez-Romero, Evgeny Revunov, Jonas Malmquist, Mikhail Kondrashov, Ryosuke Arakawa, Akihiro Takano, Aaron Smith, Joanne Wilson, Annika Janefeldt, Lin Zhang, James Atkinson, Peter Barton, Gareth Maglennon, Don X. Nguyen, Minghui Zhao, Sally J. Adua, Katarina Varnäs, Richard Goodwin, Magnus Schou, Gail L. Wrigley, Yumei Yan, Nicole Strittmatter, Peter Johnström, Kan Chen, Nicola Colclough

Supplementary Figure S1 - Structure and position of label for compounds assessed for BBB penetrance in non human primates (NHP). Majority of compounds were labelled with carbon-11 except afatinib which was labelled with fluorine-18. (*) Indicates pos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f25e8e82af5345d6a7e68e8c3a46ea5
https://doi.org/10.1158/1078-0432.22473252

Structural and functional characterization of a specific antidote for ticagrelor

Autor: Buchanan, Andrew ^*, Newton, Philip, Pehrsson, Susanne, Inghardt, Tord, Antonsson, Thomas, Svensson, Peder, Sjögren, Tove, Öster, Linda, Janefeldt, Annika, Sandinge, Ann-Sofie, Keyes, Feenagh, Austin, Mark, Spooner, Jennifer, Gennemark, Peter, Penney, Mark, Howells, Garnet, Vaughan, Tristan, Nylander, Sven ^*

Publikováno v: In Blood 28 May 2015 125(22):3484-3490

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

Autor: Aaron Smith, Peter Johnström, Katarina Varnäs, James Atkinson, Minghui Zhao, Nicole Strittmatter, Yumei Yan, Ryosuke Arakawa, Nicola Colclough, Annika Janefeldt, M. Raymond V. Finlay, Albert D. Windhorst, Evgeny Revunov, Natasha A. Karp, Kan Chen, Lin Zhang, Gareth Maglennon, Peter Barton, Richard J. A. Goodwin, Ana Vazquez-Romero, Magnus Schou, Akihiro Takano, Gail L. Wrigley, Darren Cross, Mikhail Kondrashov, Mohammad Mahdi Moein, Zack Cheng, Paul D. Smith, Sally J. Adua, Richard A. Ward, Lars Farde, James W.T. Yates, Joanne Wilson, Jonas Malmquist, Don X. Nguyen

Publikováno v: Colclough, N, Chen, K, Johnstrom, P, Strittmatter, N, Yan, Y, Wrigley, G L, Schou, M, Goodwin, R, Varnas, K, Adua, S J, Zhao, M, Nguyen, D X, Maglennon, G, Barton, P, Atkinson, J, Zhang, L, Janefeldt, A, Wilson, J, Smith, A, Takano, A, Arakawa, R, Kondrashov, M, Malmquist, J, Revunov, E, Vazquez-Romero, A, Moein, M M, Windhorst, A D, Karp, N A, Finlay, R V, Ward, R A, Yates, J W T, Smith, P D, Farde, L, Cheng, Z & Cross, D A E 2021, ' Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs ', Clinical Cancer Research, vol. 27, no. 1, pp. 189-201 . https://doi.org/10.1158/1078-0432.CCR-19-1871
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.

Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–brain barrier (BBB) permeability is considered desirable for incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d134e34f16839af3ef1a834fbea0f94
https://doi.org/10.1158/1078-0432.ccr-19-1871

Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452.

Autor: Sandinge, Ann-Sofie¹ ann-sofie.sandinge@astrazeneca.com, Janefeldt, Annika¹, Pehrsson, Susanne¹, Nylander, Sven¹

Publikováno v: PLoS ONE. 7/26/2018, Vol. 13 Issue 7, p1-14. 14p.